His primary areas of study are Angiogenesis, Neovascularization, Cancer research, Cell biology and Immunology. His Angiogenesis study combines topics in areas such as Endothelial stem cell, Endocrinology and Pathology. The various areas that Domenico Ribatti examines in his Neovascularization study include Mast cell, Tryptase, B cell, Fibroblast growth factor and Tumor angiogenesis.
He studied Cancer research and Bone marrow that intersect with Monoclonal gammopathy of undetermined significance and Stromal cell. His Cell biology research is multidisciplinary, incorporating perspectives in Blood vessel, Cellular differentiation, Vascular endothelial growth factor B, Integrin and Endothelium. Domenico Ribatti has researched Immunology in several fields, including Receptor and Metastasis, Lymphangiogenesis.
Domenico Ribatti mainly investigates Angiogenesis, Cancer research, Pathology, Cell biology and Immunology. His Angiogenesis study combines topics from a wide range of disciplines, such as Vascular endothelial growth factor and In vivo. His work focuses on many connections between Cancer research and other disciplines, such as Bone marrow, that overlap with his field of interest in Multiple myeloma and Monoclonal gammopathy of undetermined significance.
His study in Pathology is interdisciplinary in nature, drawing from both Mast cell and Tryptase. He works mostly in the field of Cell biology, limiting it down to topics relating to Endothelial stem cell and, in certain cases, Matrigel. His research in Internal medicine intersects with topics in Endocrinology and Oncology.
Domenico Ribatti mainly focuses on Angiogenesis, Cancer research, Cell biology, Pathology and Inflammation. His Angiogenesis research is mostly focused on the topic Chorioallantoic membrane. As a part of the same scientific family, Domenico Ribatti mostly works in the field of Cancer research, focusing on Tumor progression and, on occasion, Cell.
The concepts of his Pathology study are interwoven with issues in Mast cell and Hematology, Internal medicine. Domenico Ribatti usually deals with Inflammation and limits it to topics linked to Fibrosis and Epithelial–mesenchymal transition. The study incorporates disciplines such as CD68 and Lymphoma in addition to Tumor microenvironment.
His primary scientific interests are in Angiogenesis, Cancer research, Pathology, Tumor progression and Inflammation. The Angiogenesis study combines topics in areas such as Mast cell, Tumor microenvironment, Cell biology, Bone marrow and In vivo. He combines subjects such as Monoclonal gammopathy of undetermined significance and Multiple myeloma with his study of Bone marrow.
His studies deal with areas such as Cell, Cancer, Metastasis, Cytokine and Growth factor as well as Cancer research. His Pathology research includes elements of Internal medicine and Tryptase. His Inflammation research integrates issues from Fibrosis, Wound healing, Neovascularization and Immune system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Bone marrow angiogenesis and progression in multiple myeloma.
Angelo Vacca;Domenico Ribatti;Luisa Roncali;Girolamo Ranieri.
British Journal of Haematology (1994)
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Angelo Vacca;Domenico Ribatti;Marco Presta;Monica Minischetti.
Blood (1999)
Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo
Domenico Ribatti;Domenico Ribatti;Marco Presta;Marco Presta;Angelo Vacca;Angelo Vacca;Roberto Ria;Roberto Ria.
Blood (1999)
Mast cells, angiogenesis, and tumour growth
Domenico Ribatti;Enrico Crivellato.
Biochimica et Biophysica Acta (2012)
The role of pericytes in angiogenesis
Domenico Ribatti;Beatrice Nico;Enrico Crivellato.
The International Journal of Developmental Biology (2011)
Broad targeting of angiogenesis for cancer prevention and therapy
Zongwei Wang;Charlotta Dabrosin;Xin Yin;Mark M. Fuster.
Seminars in Cancer Biology (2015)
Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic
Marina Ziche;D. Maglione;D. Ribatti;Lucia Morbidelli.
Laboratory Investigation (1997)
Vascular Damage and Anti-angiogenic Effects of Tumor Vessel-Targeted Liposomal Chemotherapy
Fabio Pastorino;Chiara Brignole;Danilo Marimpietri;Michele Cilli.
Cancer Research (2003)
Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Girolarno Ranieri;Rosa Patruno;Eustachio Ruggieri;Severino Montemurro.
Current Medicinal Chemistry (2006)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Aldo Maria Roccaro;Teru Hideshima;Noopur Raje;Shaji Kumar.
Cancer Research (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Bari Aldo Moro
University of Bari Aldo Moro
University of Brescia
University of Bari Aldo Moro
University of Padua
Istituto Giannina Gaslini
University of Brescia
Boston Children's Hospital
University of Chieti-Pescara
University of Bari Aldo Moro
TU Wien
Georgia Institute of Technology
MIT
Ludwig-Maximilians-Universität München
Microsoft (United States)
Université Paris Cité
University of Illinois at Chicago
Hokkaido University
Forschungszentrum Jülich
Icahn School of Medicine at Mount Sinai
Fukuoka Women's University
École Polytechnique Fédérale de Lausanne
University of Toronto
Technical University of Munich
Simon Fraser University
United States Department of Veterans Affairs